Scotiabank Maintains Sector Perform on Apellis Pharmaceuticals, Lowers Price Target to $20

Benzinga · 05/08 14:15
Scotiabank analyst Greg Harrison maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Sector Perform and lowers the price target from $28 to $20.